SCHEDULE: Janus Henderson Discloses Bright Minds Biosciences Stake

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 13.1% of Bright Minds Biosciences Inc. common stock as of March 31, 2026.

Summary

• Janus Henderson Group plc (JHG) has filed an amendment to its Schedule 13G, indicating its beneficial ownership of Bright Minds Biosciences Inc. common stock.
• As of March 31, 2026, JHG, through its various asset management subsidiaries, beneficially owns 1,284,324 shares of Bright Minds Biosciences Inc. common stock.
• This represents 13.1% of the total class of securities.
• JHG disclaims beneficial ownership of shares held in Managed Portfolios where it exercises investment and/or voting discretion, as the Asset Managers do not have the right to receive dividends or sale proceeds from these securities.
• The filing specifies that the Janus Henderson Biotech Innovation Master Fund Ltd. is the only Managed Portfolio with the right to receive dividends or sale proceeds from more than five percent of the common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of beneficial ownership by a large investment manager, indicating a significant but not controlling stake, without providing operational or financial performance details of the underlying company.

Positives

• Janus Henderson Group plc, a significant investment management firm, has disclosed a substantial stake (13.1%) in Bright Minds Biosciences Inc., which could signal confidence in the company's prospects.
• The filing indicates that the company's securities are held in the ordinary course of business and not for the purpose of influencing control, suggesting a standard investment approach.

Negatives

• The filing explicitly states that the Asset Managers do not have the right to receive dividends or the proceeds from the sale of securities held in Managed Portfolios, meaning JHG itself does not directly benefit from these holdings.
• The disclosure is made by a parent holding company, with beneficial ownership attributed to various asset managers, which can add a layer of complexity in understanding direct control or influence.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company itself.
• Potential risks for Janus Henderson Group plc could include market volatility affecting the value of their investment in Bright Minds Biosciences Inc.
• There is a risk that the investment strategy of the Managed Portfolios may not align with the long-term interests of Bright Minds Biosciences Inc. if the Asset Managers' discretion is exercised without direct benefit to JHG.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Janus Henderson Group plc regarding their investment in Bright Minds Biosciences Inc. It is a disclosure of current beneficial ownership.

Management Comments

• "The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios)."
• "As a result of their exercise of investment and/or voting discretion on behalf of the Managed Portfolios, the Asset Managers may be deemed to be the beneficial owner of 1,284,324 common stock of Bright Minds Biosciences, Inc."
• "However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights."
• "The Managed Portfolios have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts."
• "Due to an irrevocable delegation of investment and voting discretion to an Asset Manager on less than 60 days notice, the Fund is not considered a Reporting Person under Section 13(d) and (g)."

Industry Context

StockSavvy.ai notes that significant institutional ownership, as disclosed by Janus Henderson Group plc, is a common indicator of investor confidence in the biotechnology sector, particularly for companies like Bright Minds Biosciences Inc. that are often subject to substantial investment by specialized funds.

Stakeholder Impact

• Shareholders of Bright Minds Biosciences Inc.: The disclosure of a significant stake by Janus Henderson Group plc may be viewed positively, potentially indicating institutional confidence and possibly leading to increased investor interest.
• Janus Henderson Group plc: The investment represents a portion of their managed portfolios, and its performance will impact the overall returns of those portfolios.
• Asset Managers within Janus Henderson Group: These entities exercise discretion over the shares, and their investment decisions will be guided by their respective mandates.

Next Steps

• Janus Henderson Group plc will continue to hold its beneficial ownership in Bright Minds Biosciences Inc. unless it decides to alter its holdings.
• The company will be required to file amendments to this Schedule 13G if there are any material changes in its beneficial ownership.

Key Dates

Keywords

Schedule 13G, Janus Henderson Group plc, Bright Minds Biosciences Inc., Beneficial Ownership, Common Stock, Investment Management, SEC Filing, Securities Exchange Act of 1934, Asset Managers